This article was originally published in The Gray Sheet
Executive SummaryPulmonary drug delivery system firm's $43.2 mil. initial public offering Nov. 10 includes 3.6 mil. shares at $12 each. The Sunnyvale, California firm notes that its first nebulizer, the FDA-approved portable AeroNeb, is targeted for launch in the first half of 2001. AeroGen also is developing AeroDose inhalers. Chase H&Q was lead manager for the IPO; CIBC World Markets and SG Cowen were co-managers. The underwriters hold a 30-day over-allotment option for up to an additional 540,000 shares
You may also be interested in...
Grail announced it will enroll about 6,200 people in an interventional, multi-center study evaluating its multi-cancer early-detection blood test. This is the first time health care providers will use this test to help guide patient care.
As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.
Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.